Intratumoral CD73: An immune checkpoint shaping an inhibitory tumor microenvironment and implicating poor prognosis in Chinese melanoma cohorts

Gao, Zixu; Wang, Lu; Song, Zhengqing; Ren, Mingchun; Yang, Yang; Li, Jianrui; Shen, Kangjie; Li, Yinlam; Ding, Yiteng; Yang, Yanwen; Zhou, Yuhong; Wei, Chuan‐Yuan; Gu, Jianying

doi:10.3389/fimmu.2022.954039

Cited by 9 publications

(6 citation statements)

References 69 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Recent studies have emphasized the integral relationship between tumor immune microenvironment and tumor initiation and progression [26][27][28].…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Construction of a necroptosis-related lncRNA signature for predicting prognosis and revealing the immune microenvironment in bladder cancer

Wang,

Jiang,

Wang

et al. 2024

Aging

View full text Add to dashboard Cite

Background: Bladder cancer (BCa) is a common malignancy in the urinary system. Necroptosis, a recently discovered form of programmed cell death, is closely associated with the development and progression of various types of tumors. Targeting necroptosis through anti-cancer strategies has shown potential as a therapy for cancer. We aimed to develop a necroptosis-related lncRNAs (NRlncRNAs) risk model that can predict the survival and tumor immunity of BCa patients. Methods: We analyzed sequencing data obtained from the TCGA database, and applied least absolute shrinkage and selection operator (LASSO) and Cox regression analysis to identify crucial NRlncRNAs for building a risk model. Using the risk score, we categorized patients into high-and low-risk groups, and assessed the accuracy with the area under the receiver operating characteristic (AUROC) and Kaplan-Meier curves. We performed the RT-qPCR to detect the expression differences of the genes based on the risk model. Results: We identified a total of 296 NRlncRNAs, and 6 of them were included in the prognostic model. The AUC values for 1-, 3-, and 5-year predictions were 0.675, 0.726 and 0.734, respectively. Our risk model demonstrated excellent predictive performance and served as an independent predictor with high predictive power. Additionally, we performed PCA, TMB, GSEA analyses, and evaluated immune cell infiltration, to reveal significant differences between the high-and low-risk groups in functional signaling pathways, immunological status, and mutation profiles. Finally, we assessed the chemotherapeutic response of several drugs. According to the RT-qPCR results, we found that four NRlncRNAs of the risk model were more highly expressed in BCa cell lines than human immortalized uroepithelial cell line and regulated the occurrence and progression of bladder cancer. Conclusion: We constructed a novel NRlncRNAs-associated risk model, which could predict the prognosis and immune response of BCa patients.

show abstract

“…Recent studies have emphasized the integral relationship between tumor immune microenvironment and tumor initiation and progression [26][27][28].…”

Section: Discussionmentioning

confidence: 99%

“…Recent studies have emphasized the integral relationship between tumor immune microenvironment and tumor initiation and progression [ 26 – 28 ]. Immunocyte infiltration serves as a regulator of tumor progression, influencing prognosis by reshaping the tumor microenvironment [ 29 ].…”

Section: Discussionmentioning

confidence: 99%

Construction of a necroptosis-related lncRNA signature for predicting prognosis and revealing the immune microenvironment in bladder cancer

Wang,

Jiang,

Wang

et al. 2024

Aging

View full text Add to dashboard Cite

show abstract

“…The B16F0 (RRID: (CVCL_0604)) and B16F10 (RRID: (CVCL_0159)) cell lines purchased from the Cell Bank of the Chinese Academy of Sciences (Shanghai, China) were cultured as previous reported [ 70 ]. CMV-Luc-Puro lentiviral vectors (Genomeditech, Shanghai, China) were transfected into B16F0 and B16F10 cells and used for the bioluminescence assay.…”

Section: Methodsmentioning

confidence: 99%

Decoding the metastatic potential and optimal postoperative adjuvant therapy of melanoma based on metastasis score

Shen,

Song,

Wang

et al. 2023

Cell Death Discov.

Self Cite

View full text Add to dashboard Cite

Metastasis is a formidable challenge in the prognosis of melanoma. Accurately predicting the metastatic potential of non-metastatic melanoma (NMM) and determining effective postoperative adjuvant treatments for inhibiting metastasis remain uncertain. In this study, we conducted comprehensive analyses of melanoma metastases using bulk and single-cell RNA sequencing data, enabling the construction of a metastasis score (MET score) through diverse machine-learning algorithms. The reliability and robustness of the MET score were validated using various in vitro assays and in vivo models. Our findings revealed a distinct molecular landscape in metastatic melanoma characterized by the enrichment of metastasis-related pathways, intricate cell–cell communication, and heightened infiltration of pro-angiogenic tumor-associated macrophages compared to NMM. Importantly, patients in the high MET score group exhibited poorer prognoses and an immunosuppressive microenvironment, featuring increased infiltration of regulatory T cells and decreased infiltration of CD8+ T cells, compared to the low MET score patient group. Expression of PD-1 was markedly higher in patients with low MET scores. Anti-PD-1 (aPD-1) therapy profoundly affected antitumor immunity activation and metastasis inhibition in these patients. In summary, our study demonstrates the effectiveness of the MET score in predicting melanoma metastatic potential. For patients with low MET scores, aPD-1 therapy may be a potential treatment strategy to inhibit metastasis. Patients with high MET scores may benefit from combination therapies.

show abstract

“…In melanoma, CD73 high tumors exhibit fewer infiltrating CD8+ T cells and CD56+ NK cells infiltration [32]. In vitro, primary human melanoma cell lines suppress T cell proliferation through the CD73/adenosine pathway [24].…”

Section: T Cellsmentioning

confidence: 99%

Unraveling the Intricacies of CD73/Adenosine Signaling: The Pulmonary Immune and Stromal Microenvironment in Lung Cancer

Saigí,

Mesía-Carbonell,

Barbie

et al. 2023

Cancers

View full text Add to dashboard Cite

CD73 and adenosine have gained prominence in lung cancer research. The NT5E gene encodes CD73, known as an ectonucleotidase, which plays a crucial role within tumor cells, with immune-suppressive properties. Beyond cancer, CD73 exerts an influence on cardiac, neural, and renal functions, affecting cardiac, neural, and renal functions. CD73’s significance lies in its production of extracellular adenosine. It is notably expressed across diverse cell types within the immune and stromal lung microenvironment. CD73 expression amplifies in lung tumors, especially non-small cell lung cancer (NSCLC), often aligned with key oncogenic drivers like mutant EGFR and KRAS. CD73/adenosine pathway seems to be involved in tumoral immunoevasion, hampering the use of the immune checkpoint inhibitor (ICI) and correlating with therapy resistance. Despite the partial success of current ICI therapies, the CD73/adenosine pathway offers promise in enhancing their effectiveness. This comprehensive review explores recent insights into lung cancer’s CD73/adenosine pathway. It explores roles within tumor cells, the lung’s stromal environment, and the immune system. Ranging from pre-clinical models to clinical trials, potential therapies targeting the adenosine pathway for lung cancer treatment are discussed below.

show abstract

Intratumoral CD73: An immune checkpoint shaping an inhibitory tumor microenvironment and implicating poor prognosis in Chinese melanoma cohorts

Cited by 9 publications

References 69 publications

Construction of a necroptosis-related lncRNA signature for predicting prognosis and revealing the immune microenvironment in bladder cancer

Construction of a necroptosis-related lncRNA signature for predicting prognosis and revealing the immune microenvironment in bladder cancer

Decoding the metastatic potential and optimal postoperative adjuvant therapy of melanoma based on metastasis score

Unraveling the Intricacies of CD73/Adenosine Signaling: The Pulmonary Immune and Stromal Microenvironment in Lung Cancer

Contact Info

Product

Resources

About